EFPIA患者W.A.I.T.指标2025

Published May 2026 Max Newton,Principal, Global Strategic Partners (GS&AR)Kelsey Stoddart,SrConsultant, Global Supplier & Association RelationsMarco Travaglio,Consultant, Global Supplier & Association RelationsEmily Heron,Analyst, Global Supplier & Association Relations © 2026. All rights reserved. IQVIA®is a registered trademark of IQVIA Inc. in the United States, the European Union, and various other countries. Foreword Indicators measure availability, restrictions to availability and time to availability The Patients W.A.I.T. (Waiting toAccessInnovativeTherapies) Indicator hasbeen running in evolving formats since 2004 and has offered acomprehensive overview of public reimbursement across over 30 countriessince 2018. Long-running The Patients W.A.I.T. Indicatorstudy has been running in evolvingformats since 2004 However, the relevance of whether an innovative molecule is included onpublic reimbursement lists has diminished over the years, with a rise inpatient access through alternative channels and/or with restrictions. This year’s iteration of the report retains the core availability metrics, whilstadding additional context around the positioning of the report within thebroader access landscape, and greater granularity on the level ofrestrictions to patient access (i.e. individual patient only). These updatesaim to ensure the report remains relevant in new access landscape andsupport the accurate use of the W.A.I.T. report. Broad coverage The Patients W.A.I.T. dataset covers36 countries and 4 years of novelmedicine approvals, with a historicdataset covering 11-years of data Information on the availability of 168 innovative medicines with central-marketing authorisation between 2021 and 2024 are included in the report.There is a one-year delay to permit countries to include these medicines ontheir public reimbursement list, meaning that the data on availability isaccurate as ofJanuary 5th2026. Widely referenced The Patients W.A.I.T. report is used byall stakeholders to inform regionaland national discussions on patientaccess Local pharmaceutical industry associations provide the information directlyto IQVIA and EFPIA, and their definitions are included within the appendixto ensure full transparency. Contents •Background •The Patients W.A.I.T. indicators 1.Overview (all products)2.Oncology3.Orphan medicines4.Non-oncology orphan medicines5.Combination therapies6.Historic comparisons and extended period •Methodology and definitions The study is based on the core concept of “availability” Definition of availability Inclusion of a centrally-approvedmedicine on the publicreimbursement list in a country Where appropriate it takes into consideration things like managedentry agreements, line-of-therapy or formulary restrictions.However, itdoes nothave a correlation to the use / uptake of themedicines. In this study the term‘availability’is used throughoutto permit standardisedmeasurement across 36healthcare systems Country-specific nuances should be discussed with the localassociations or EFPIA directly to ensure correct interpretationof the data, please see the appendix for further details. The access landscape in Europe has continued to evolve Historically, full availability was the main access route; now, restrictions are commonplace The Patients W.A.I.T. Indicator provides a comprehensive viewof key components of access to innovative medicines Elements of the picture exist in other reports and studies, while others remain unknown Contents •Background •The Patients W.A.I.T. indicators 1.Overview (all products)2.Oncology3.Orphan medicines4.Non-oncology orphan medicines5.Combination therapies6.Historic comparisons and extended period •Methodology and definitions Patients W.A.I.T. Indicator 2025Survey: Executive summary Notes for consideration 1.Availability over time:The availabilitylandscape remains largely similar to theprevious survey, with the overall profile ofaccess routes broadly unchanged (fullavailability 28% vs 29% in 2024; limitedavailability remaining a significant shareat 17%) EU average rate of full availabilityremains at asimilar levelto lastyear(29% in 2024 study) 28% EU average rate of limitedavailabilityremains a significantproportionofall products 17% 2.Time to availability:Delays to patientaccess have increased since the 2019survey, with the average time to patientaccess rising from 504 days to 597 days 597days EU average time to availabilityisover19 days longerthan theprevious study (578 days in 2024study) 3.WAIT indicator scope:Thestudyshowspublicly listed availability and restrictionsto access, and was created to permit acomparison of European access; it doesnot capture all nuances of patient accessin all countries, but is supplemented byother referenced studies Access disparityremains >80%between the highest and lowestEuropean country for multiplestudies 88% 1. Overview (all products) Indicators: 1.1.Total availability by approval year1.